Jubilant Pharmova Limited has informed the Exchange about General Updates
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova's Board met on July 29, 2025 and approved two key items. First, Deloitte Touche Tohmatsu India LLP has been re-appointed as Internal Auditors for a 3-year term covering FY 2025-26 to FY 2027-28, ensuring continuity in the company's internal audit function. Second, the Board approved the grant of 1,21,560 Stock Options and Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. The exercise price is set at Re. 1 per share (face value), with vesting linked to performance criteria and service tenure over 1 to 5 years. This is part of the company's regular employee incentive and governance practices.
The auditor re-appointment signals continued governance stability with a reputed firm, while the ESOP grant at face value is a positive retention and motivation tool for employees, with mild potential dilution of about 0.07% based on total equity shares outstanding.